Update on systemic treatment in early triple negative breast cancer

被引：29

作者：

Nunez Abad, Martin ^{[1
]}

Calabuig-Farinas, Silvia ^{[2
,4
,5
,6
,7
]}

Lobo de Mena, Miriam ^{[1
]}

Sanz de Bremond, Maria Jose Godes ^{[1
]}

Garcia Gonzalez, Clara ^{[1
]}

Torres Martinez, Susana ^{[2
,4
]}

Angel Garcia-Garcia, Jose ^{[8
]}

Iranzo Gonzalez-Cruz, Vega ^{[1
,2
,3
]}

Camps Herrero, Carlos ^{[1
,2
,4
,6
,7
]}

机构：

[1] Univ Gen Hosp Valencia, Dept Med Oncol, Tres Cruces 2, Valencia 46014, Spain

[2] CIBERONC, Madrid, Spain

[3] Univ Valencia, Dept Med, Valencia, Spain

[4] Univ Gen Hosp Valencia, Gen Univ Hosp Res Fdn, Mol Oncol Lab, Valencia, Spain

[5] Univ Valencia, Dept Pathol, Valencia, Spain

[6] Principe Felipe Res Ctr, Mixed Unit TRIAL, Valencia, Spain

[7] Gen Univ Hosp Valencia Res Fdn, Valencia, Spain

[8] Univ Gen Hosp Valencia, Dept Pathol Anat, Valencia, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

chemotherapy; immunotherapy; neoadjuvant therapy; precision medicine; systemic treatment; triple negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; OPEN-LABEL; PREOPERATIVE DOXORUBICIN; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PACLITAXEL; CYCLOPHOSPHAMIDE;

D O I：

10.1177/1758835920986749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

引用

页数：18

共 50 条

[21] Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Diana, Anna
Carlino, Francesca
Franzese, Elisena
Oikonomidou, Olga
Criscitiello, Carmen
De Vita, Ferdinando
Ciardiello, Fortunato
Orditura, Michele
CANCERS, 2020, 12 (04)
[22] Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Lee, Jieun
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
[23] Immunotherapy Treatment for Triple Negative Breast Cancer
Berger, Elizabeth R.
Park, Tristen
Saridakis, Angeleke
Golshan, Mehra
Greenup, Rachel A.
Ahuja, Nita
PHARMACEUTICALS, 2021, 14 (08)
[24] Treatment Progress in Triple Negative Breast Cancer
Kraemer, Stefan
Rogmans, Christoph
Saylan, Dilek
Friedrich, Dominique
Kraft, Clayton
Rogmans, Gunther
Wirtz, Marina
Friedrich, Michael
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (02) : 341 - 352
[25] Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer
Rauch, Gaiane Margishvili
Candelaria, Rosalind P.
Guirguis, Mary Saber
Boge, Medine
Mohamed, Rania M. M.
Elshafeey, Nabil
Sun, Jia
Whitman, Gary J.
Leung, Jessica
Le-Petross, Huong C.
Santiago, Lumarie
Lane, Deanna
Scoggins, Marion
Spak, David
Patel, Miral M.
Perez, Frances
White, Jason B.
Ravenberg, Elizabeth
Peng, Wei
Tripathy, Debu
Valero, Vicente
Litton, Jennifer
Huo, Lei
Yam, Clinton
Thompson, Alastair
Ma, Jingfei
Moulder, Stacy L.
Yang, Wei
Adrada, Beatriz E.
CANCER RESEARCH, 2022, 82 (04)
[26] Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo
Binghe Xu
Frontiers of Medicine, 2021, 15 (01) : 1 - 10
[27] Progress in systemic therapy for triple-negative breast cancer
Mo, Hongnan
Xu, Binghe
FRONTIERS OF MEDICINE, 2021, 15 (01) : 1 - 10
[28] Triple negative breast cancer: proven and promising systemic therapies
Bergin, Alice
Oakman, Catherine
Lindeman, Geoffrey J.
CANCER FORUM, 2016, 40 (03) : 20 - 25
[29] Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo
Binghe Xu
Frontiers of Medicine, 2021, 15 : 1 - 10
[30] Carboplatin for early triple- negative breast cancer?
Valero, Vicente
LANCET ONCOLOGY, 2014, 15 (07): : 676 - 678

← 1 2 3 4 5 →